Human Antibodies Against Middle East Respiratory Syndrome Coronavirus


No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines.

The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection.  Researchers at the NCI have developed human antibodies that target MERS-CoV.  Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralizing the virus as demonstrated in a pseudovirus assay.



Potential Commercial Applications: Competitive Advantages:
  • Antibody-based therapeutics for treatment of MERS-CoV infection
 
  • No vaccine or other biologic therapy is available, and this antibody provides high binding (sub-nanomolar) affinity, and relative safety with long half-lives.


Development Stage:
Discovery (Lead Identification)

Inventors:

Dimiter Dimitrov (NCI)  ➽ more inventions...

Tianlei Ying (NCI)  ➽ more inventions...

Tina Ju ()  ➽ more inventions...

Kwok Yuen ()  ➽ more inventions...


Intellectual Property:
U.S. Application No. 61/892,750

Publications:
Zaki AM, et al. PMID 23075143
Zhu Z, et al. PMID 18271743
Zhu Z, et al. PMID 17620608

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-002-2014
Updated: May 30, 2018